Nelson Vergel
Founder, ExcelMale.com
The FDA's Pharmacy Compounding Advisory Committee (PCAC) met July 23 and 24 and voted on whether seven peptides belong on the Section 503A Bulk Drug Substances List, the list that lets a licensed compounding pharmacy legally prepare a peptide against an individual prescription. Six passed. One didn't.
The vote
What this actually means
This is a recommendation. FDA hasn't made a final decision. PCAC votes are non-binding, and FDA still has to complete formal rulemaking, a proposed rule, a comment period, then a final rule, before any of these six can legally be compounded under 503A. That process has typically taken well over a year to reach even a proposed rule after a positive vote. Realistic pharmacy access is more likely sometime in 2027.
None of these are FDA-approved drugs. If FDA finalizes the recommendation, a licensed pharmacist can compound the bulk substance against a valid prescription. That's different from FDA certifying any of them safe and effective for a specific condition.
This vote only covers 503A. It says nothing about 503B outsourcing facilities, which sit under a separate framework with their own bulks list.
Why FDA's own scientists disagreed
FDA's career scientists recommended against all seven substances in their briefing documents. Their objections:
The committee overruled its own agency's scientists on six of seven votes. Part of the reason: FDA added eight temporary voting members to PCAC in June. Kennedy's office nominated them, and six have sold peptide products themselves. On BPC-157, KPV, and TB-500, all eight new members voted yes as a bloc. That drew public conflict-of-interest criticism before and during the meeting.
Why DSIP was the one rejected
Emideltide (DSIP) has the longest human research history of the seven, studied since 1981, mostly for insomnia and opioid withdrawal. That made its rejection the meeting's biggest surprise. Panelists raised a mechanistic concern: DSIP stimulates endorphin release, and several worried that resembled the reward-pathway activity of addictive drugs. It lost by a single vote.
What's next
A second PCAC meeting is scheduled before the end of February 2027 to review five more peptides that came off the Category 2 restricted list alongside this batch: LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF.
CJC-1295 was never part of either docket. It's classified as a developmental drug rather than a bulk substance, so it stays off-limits regardless of how this process plays out.
Where this leaves compounding pharmacies
Empower Pharmacy, one of the largest 503A/503B compounding operations in the country, submitted formal comments in July backing all seven substances, including DSIP, arguing that regulated compounding access is safer for patients than gray-market and overseas suppliers. After the vote, Empower said it's ready to compound these substances as soon as FDA finalizes the recommendation.
Three years ago, these peptides were banned outright for compounding. That's changing now. FDA still needs to finalize the rule before compounding becomes legal.
This post reflects publicly available regulatory news and isn't medical advice. Talk to your prescriber before starting or changing any peptide therapy.
Sources
The vote
- BPC-157: passed 8-6-1 (yes-no-abstain)
- KPV: passed 8-6-1
- TB-500: passed 8-6-1
- MOTS-c: passed, narrower margin, two abstentions
- Semax: passed 8-5
- Epitalon: passed 7-4
- Emideltide (DSIP): rejected 6-7, the closest vote of the two days
What this actually means
This is a recommendation. FDA hasn't made a final decision. PCAC votes are non-binding, and FDA still has to complete formal rulemaking, a proposed rule, a comment period, then a final rule, before any of these six can legally be compounded under 503A. That process has typically taken well over a year to reach even a proposed rule after a positive vote. Realistic pharmacy access is more likely sometime in 2027.
None of these are FDA-approved drugs. If FDA finalizes the recommendation, a licensed pharmacist can compound the bulk substance against a valid prescription. That's different from FDA certifying any of them safe and effective for a specific condition.
This vote only covers 503A. It says nothing about 503B outsourcing facilities, which sit under a separate framework with their own bulks list.
Why FDA's own scientists disagreed
FDA's career scientists recommended against all seven substances in their briefing documents. Their objections:
- No human trial data at all for KPV, TB-500, or MOTS-c
- Small, poorly controlled studies for BPC-157, Emideltide, and Semax
- Adverse event reports for BPC-157
- MOTS-c and TB-500 both carry World Anti-Doping Agency prohibited status
The committee overruled its own agency's scientists on six of seven votes. Part of the reason: FDA added eight temporary voting members to PCAC in June. Kennedy's office nominated them, and six have sold peptide products themselves. On BPC-157, KPV, and TB-500, all eight new members voted yes as a bloc. That drew public conflict-of-interest criticism before and during the meeting.
Why DSIP was the one rejected
Emideltide (DSIP) has the longest human research history of the seven, studied since 1981, mostly for insomnia and opioid withdrawal. That made its rejection the meeting's biggest surprise. Panelists raised a mechanistic concern: DSIP stimulates endorphin release, and several worried that resembled the reward-pathway activity of addictive drugs. It lost by a single vote.
What's next
A second PCAC meeting is scheduled before the end of February 2027 to review five more peptides that came off the Category 2 restricted list alongside this batch: LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF.
CJC-1295 was never part of either docket. It's classified as a developmental drug rather than a bulk substance, so it stays off-limits regardless of how this process plays out.
Where this leaves compounding pharmacies
Empower Pharmacy, one of the largest 503A/503B compounding operations in the country, submitted formal comments in July backing all seven substances, including DSIP, arguing that regulated compounding access is safer for patients than gray-market and overseas suppliers. After the vote, Empower said it's ready to compound these substances as soon as FDA finalizes the recommendation.
Three years ago, these peptides were banned outright for compounding. That's changing now. FDA still needs to finalize the rule before compounding becomes legal.
This post reflects publicly available regulatory news and isn't medical advice. Talk to your prescriber before starting or changing any peptide therapy.
Sources
Start Here (2K views)
